Bone marrow angiogenesis in myeloma and its precursor disease: A prospective clinical trial

Leukemia

Volumn 28, Issue 2, 2014, Pages 413-416

  Bhutani, M ^a   Turkbey, B ^b   Tan, E ^a   Kemp, T J ^c   Pinto, L A ^c   Berg, A R ^a   Korde, N ^a   Minter, A R ^a   Weiss, B M ^a,e   Mena, E ^b   Lindenberg, L ^b   Aras, O ^b,f   Purdue, M P ^b   Hofmann, J N ^b   Steinberg, S M ^b   Calvo, K R ^d   Choyke, P L ^b   Maric, I ^d   Kurdziel, K ^b   Landgren, O ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d CCR   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW; HUMANS; MAGNETIC RESONANCE IMAGING; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84893752163     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.268     Document Type: Letter

References (15)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
2. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Sem Oncol 2001; 28: 543-550.
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
4. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
5. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216.
6. Hillengass J, Zechmann C, Bauerle T, Wagner-Gund B, Heiss C, Benner A et al. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 2009; 15: 3118-3125.
7. Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H et al. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2004; 176: 1285-1295.
8. Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O. Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma 2011; 52: 1630-1640.
9. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199.
10. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104: 1159-1165.
11. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R et al. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003; 123: 305-308.
12. Cibeira MT, Rozman M, Segarra M, Lozano E, Rosinol L, Cid MC et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008; 41: 244-253.
13. Sucak GT, Aki SZ, Yuzbasioglu B, Akyurek N, Yagci M, Bagriacik U et al. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma 2011; 52: 1281-1289.
14. Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M et al. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57\+ cytotoxic T cells as predictors of outcome. Haematologica 2007; 92: 1075-1082.
15. Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210-217.